MediPrint Ophthalmics Advances Glaucoma Program, Expands Patent Portfolio, and Prepares for Key Industry Presentation

SAN DIEGO--(BUSINESS WIRE)--MediPrint® Ophthalmics, a clinical-stage ophthalmic drug delivery company, continues to advance its innovative glaucoma program following the successful completion of its Phase 2b clinical trial for LL-BMT1. As the company progresses towards the next phase of development, MediPrint anticipates meeting with the U.S. Food and Drug Administration (FDA) in 2025 to discuss preparations for Phase 3 clinical studies. Regulatory Progress and Path Toward Phase 3 Following the